Pivotal bioVenture Partners Investment Advisor LLC
Annual return '25
+16.4%
SPY '25
+17.7%
Alpha
-1.3ptsvs SPY
Invested
$279.8M
Holdings
13
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 96%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$PCVX
VAXCYTE INC
Q1 2026: Exited (was 1.37M shares)
28.5%
02
$OCS
OCULIS HOLDING AG
Q1 2026: Exited (was 2.29M shares)
16.0%
03
$EVMN
EVOMMUNE INC
Q1 2026: Exited (was 1.93M shares)
15.8%
04
$ARQT
ARCUTIS BIOTHERAPEUTICS INC
Q1 2026: Exited (was 1.37M shares)
11.4%
05
$TRVI
TREVI THERAPEUTICS INC
Q1 2026: Exited (was 1.26M shares)
6.6%
06
$IMNM
IMMUNOME INC
Q1 2026: Exited (was 732.5k shares)
5.7%
07
$MPLT
MAPLIGHT THERAPEUTICS INC
Q1 2026: Exited (was 611.4k shares)
4.4%
08
$ZBIO
ZENAS BIOPHARMA INC
Q1 2026: Exited (was 592.0k shares)
4.1%
09
$BIOA
BIOAGE LABS INC
Q1 2026: Exited (was 653.4k shares)
4.1%
10
$AVTX
AVALO THERAPEUTICS INC
Held since at least Q1 2024
1.6%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 08:30 UTC.